- Previous Close
0.8600 - Open
0.8680 - Bid 0.6790 x 200
- Ask 1.1100 x 100
- Day's Range
0.8500 - 0.9800 - 52 Week Range
0.4000 - 1.7300 - Volume
329,097 - Avg. Volume
521,667 - Market Cap (intraday)
21.797M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8100 - Earnings Date Mar 31, 2025 - Apr 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
www.abvcpharma.comRecent News: ABVC
View MorePerformance Overview: ABVC
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABVC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABVC
View MoreValuation Measures
Market Cap
20.38M
Enterprise Value
22.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.94
Price/Book (mrq)
2.44
Enterprise Value/Revenue
44.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.30%
Return on Equity (ttm)
-102.31%
Revenue (ttm)
509.79k
Net Income Avi to Common (ttm)
-8.24M
Diluted EPS (ttm)
-0.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
208.15k
Total Debt/Equity (mrq)
34.40%
Levered Free Cash Flow (ttm)
-2.07M